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The application of genome-wide asso-
ciation study (GWAS) approaches for the
study of genetic determinants of common
diseases has propelled human genetics
forward, resulting in a surfeit of genomic
data. With the accompanying level of
widespread collaboration and sharing of
data, access to this body of valuable
genomic data and the application of novel
analytic approaches beyond the level of
first GWAS scans is yielding additional
insights, both in terms of new genetic
discoveries and important general biolog-
ical findings [1]. However, recent work
shows that standard statistical approaches
can be applied to aggregate genome-wide
association results that place individual
research participants at increased risks for
misuse related to privacy and confidenti-
ality. We define ‘‘misuse’’ as analysis
efforts aimed at exposing individual
research participants’ information, includ-
ing revealing disease status, predicted
future likelihood or past presence of other
traits, or attempts to link another DNA
result with a participant, for example, to
determine presence or absence in a
research cohort, ancestry, and relatedness
(e.g., paternity/non-paternity). Thus,
there is the small but theoretically possible
risk of later legal or discriminatory actions
that were originally unforeseen by inves-
tigators and would likely be unwanted
and unexpected by the research partici-
pants [2–7].
At this time the risks to research
participant identification generally exist
when there is access to (at least) a
moderate number of genetic variant re-
sults that include both statistics (regression
coefficients or two-sided p-values) and
cohort-specific population allele frequen-
cies [2–5,7]. To date, scientific discussion
about these potential risks has focused
largely on theoretical scenarios and the
related ethical and policy responses [2–8].
Initial publications [2,3] resulted in signif-
icant policy shifts and reduction in the
open access to GWAS results by the
creation of controlled access repositories
for results (e.g., for the Wellcome Trust
Case Control Consortium [WTCCC]
results and Framingham Heart Study
[FHS] SHARe 100K GWAS results), but
the literature contains no systematic as-
sessment of the extent of current GWAS
results availability, temporal trends in
availability, or the number of studies that
remain at a potentially unacceptable level
of risk.
Design of Survey of Results
Availability from 643 GWASs
We conducted a systematic and chro-
nologic survey of 643 GWAS articles
published between November 2002 and
July 1, 2010. Studies were identified from
our past GWAS database effort [1] and
through the National Human Genome
Research Institute (NHGRI) catalog
(http://www.genome.gov/26525384), up-
dated and supplemented by a controlled
vocabulary search of PubMed using
QUOSA (v. 8.06.631, Waltham, MA).
Articles were retrieved by PubMed ID
using QUOSA. Abstracts and articles
were scanned to identify GWAS analyses
as opposed to other categories such as
linkage studies or studies attempting to
replicate GWAS. Linkage studies and
large-scale candidate gene studies were
not included here, though these may also
carry similar risks if they expose large
numbers of marker results. Studies that
reported only conducting copy number
variation (CNV)-based analysis were ex-
cluded (n=5). Publication dates were
determined via the NHGRI GWAS cata-
log, PubMed, or the individual publica-
tions, selecting the earliest known date of
availability. Complete supplementary ma-
terials for all 643 GWAS articles were
downloaded from journal websites or from
independent websites cited in the publica-
tions.
We also sought access to supplemental
data sources if such access required a
limited application without the additional
requirement of an Institutional Review
Board approval or other extensive approv-
als. Information was recorded on the
mode of access and the type of data that
was accessible through either open access
(via the Internet or journal content) or
through a controlled access process. If
results were available only by an applica-
tion process, we contacted the correspond-
ing author to obtain updated information.
We noted all instances for which the mode
of data access changed compared with the
access process that was stated in the
original publication.
For each GWAS manuscript, we esti-
mated the amount and type of results
available either by open access or by a
controlled access mechanism. An individ-
ual SNP result, hereafter termed ‘‘SNP-
specific result’’, refers to an association test
result with a single SNP unique within that
publication or its supplements. We placed
studies in one of five categories of
increasing ‘‘identifiability risk’’, based on
recent recommendations regarding safe
levels of data sharing [7]: category 0, no
SNP-specific results; category 1, 1–10
SNP-specific results; category 2, 11–499
SNP-specific results; category 3, 500 or
more SNP-specific results but not full
dataset level results available; or category
4, all SNP-specific results available or
potentially available. If by reviewing the
manuscript and supplemental materials we
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category, we extracted all available results
to determine the exact number of results
available. For each study we noted the
type of results available at corresponding
amounts of SNP-specific results (e.g.,
study-specific allele frequencies, individual
genotypes, regression estimates, p-values).
Few GWA studies were published
between 2002 and 2006, but the number
of published GWA studies began to grow
rapidly in 2007 (Figure 1). We identified
643 studies in the time period examined
(November 1, 2002–July 1, 2010). For the
same time period, a commonly referenced
resource, the NHGRI GWA catalog (as of
August 24, 2010), compiles 614 GWAS
studies. Ten studies from the NHGRI
GWAS catalog were not included in our
study because they focused only on CNV
analysis (n=5), or because they represent-
ed re-analyses of previously published
GWAS results (n=5). Thus, we identified
39 additional studies in the same time
period, compared with the NHGRI cata-
log, suggesting we have identified nearly
all of the published GWA studies in the
time period examined.
Data Release Mechanisms and
Temporal Trends in GWAS
Results Sharing
The number of SNP-specific results that
were made directly available upon publi-
cation of the original paper varied over a
wide range, from zero (n=5) to millions of
results. Taken as the maximum number of
SNP-association results made available,
including SNP results made available by
a controlled access application process
such as dbGAP, we observed the following
distribution of papers across the categories
defined in the Methods section: category 0
(n=5; 0.8%), category 1 (n=94; 14.6%),
category 2 (n=400; 62.2%), category 3
(n=49; 7.6%), category 4 (n=95; 14.8%).
A number of studies reported the
availability of SNP-specific genotypes for
individual research participants, usually
through a controlled access application
process; however, seven studies were
identified for which individual level geno-
type data was freely available at some
point after publication. Of these seven
studies, three required a minimal applica-
tion to access genotypes, whereas four did
not. One study made genotypes available
for download for only ,100 markers.
Another study presented genotypes via a
web browser interface that made it time-
consuming to download genotypes for
large numbers of markers. For two of the
studies that initially made individual
genotypes available through a minimal
application process, the results no longer
appear to be publicly available.
We selected a cutoff date of October 1,
2008 to define a period (‘‘post-Homer’’)
after publication of the Homer et al. [2]
report. We defined this period by allowing
approximately 1 month before this paper
likely impacted data sharing decisions in
publications. Comparing the stated results
availability in the original publications in
time periods pre- and post-October 1,
2008, we find that a smaller proportion of
studies provided access to extensive (cate-
gory 3) or full (category 4) results in the
later time period (Figure 1, p,0.006).
While there is a slight contraction in the
proportion of studies indicating possible
access to large numbers of SNP-associa-
tion results, there is a corresponding slight
increase in the proportion of studies
offering access to moderate or greater
numbers of results (category 2, 3, or 4).
This is observed in the relative growth
over time (observed in 6-month intervals)
of the proportion of studies in category 2
or 3 or 4 as opposed to the proportion in
categories 0 or 1 (Figure 1).
For those studies originally indicating
access to extensive ($500 SNP results,
category 3, n=49) or full results (category
4, n=95) at any time period (total n=144
studies), we further examined the mode by
which results were currently available as of
July 15, 2010 to gauge mechanisms of
access and whether there was indication
that any studies had changed the avail-
ability of data after their initial publica-
tion. Eighty-four of 144 studies (58.3%)
provided results that were either freely
accessible by open Internet access or by a
journal subscription. The remainder of the
studies now require formal applications for
data through some form of controlled
access and/or have results that are no
longer available via the original cited
mechanism (n=11). We assessed the
number of studies for which there was
evidence that data access models had
changed since the original publication,
and we found 35/144 studies (24.3%)
appear to have modified the level of data
access, in each case making access more
restrictive.
Finally, we assessed the number of
studies at potential risk for misuse given
a current recommended guideline of fewer
than 500 SNP-specific statistics without
provision of allele frequency information
[7]. Under these guidelines, we find that
44/643 studies (6.8%) may be at some
level of risk as of July 15, 2010. Under a
more conservative interpretation that as-
sumes that allele frequency or regression
statistics may be unnecessary for some risk
for misuse, we find that up to 79/643
studies (12.3%) may be at potential risk.
Research and Policy
Implications of GWAS Results
Availability
While extensive availability of GWAS
results may provide a small but real threat
to the privacy and confidentiality of
research participants, tight restrictions on
access to research results may inhibit
dissemination for the legitimate, scientific
use of these results [2,6,8]. Aggregate
GWAS results that are made available
are often re-used and cited as scientific
support data [1]. This practice is common
in many areas, and is well exemplified by
re-uses of data from the WTCCC, Diabe-
tes Genetic Initiative (DGI), and the FHS.
Figure 1. Temporal trends in GWAS
publications and results availability.
Top panel: Cumulative chronological release
of 643 GWAS papers at their earliest release
dates. Middle panel: Distribution of GWAS
papers among five categories of reported
maximum results availability from 2002 to
2006, and in 6-month intervals from January 1,
2007 to July 1, 2010. Bottom panel: Distribu-
tion of 643 GWAS papers among five catego-
ries of reported maximum results availability
by open access or controlled access applica-
tion in the period before October 1, 2008 (left)
and from October 1, 2008 to July 1, 2010
(right).
doi:10.1371/journal.pgen.1002269.g001
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wide-ranging and include the further
replication of known or novel genetic
signals, the construction of reference
control samples when such data are not
otherwise easily available, development of
novel methodological approaches to data
analysis, and, increasingly, the search for
evidence of pleiotropic associations for
specific loci, to gain insight into the
potential physiological mechanisms under-
lying the associations.
Since an initial effort raised privacy
concerns [2], additional efforts have re-
fined methodological approaches [3–5]
and set boundaries on the methods [4,7]
that may be used to identify individual
participants and participant disease status
in GWAS results. Discussions have fo-
cused on nuanced issues that could arise
and potential policy implementations to
address them [6,8]. In our survey of
chronological GWAS results availability
from a consecutive series of 643 published
studies, a large majority of studies (87.7%–
93.2%) appear to be in line with current
recommendations [7]. These figures may
over-estimate the proportion of studies at
risk since some studies classified as ‘‘at
potential risk’’ may have features that
make misuse more difficult, e.g., large
sample sizes with meta-analysis, combined
population allele frequency statistics only,
linkage disequilibrium between markers,
and lack of inclusion of allele frequencies
or regression statistics [4,5]. The provision
of summary statistics with minimized or
homogenized information reduces risks for
misuse. It is also important to note that we
used one of the most recent suggested
definitions of risk as greater than 500 SNP-
specific results [7]. However, a single true
threshold is unknown and depends on the
circumstances of datasets included, meth-
ods applied, and intended use, and
thresholds for risk may further evolve as
new methods are developed. A significant
number of studies that were at potential
risk given their original reported mode of
data access implemented more restrictive
measures subsequent to their initial pub-
lication. Thus, concerns raised ‘‘post-
Homer’’ have been accompanied by
measurable decisions that were voluntarily
made by scientists and/or journals.
Nonetheless, we did identify a minority
of studies that seem to be at significant risk
for potential misuse. Most alarming are a
handful of studies where individual partic-
ipant-specific genotypes are available pub-
licly. We also identified several instances
where research groups gained access to
primary GWAS results and secondarily
reported large numbers of SNP-associa-
tion results, potentially exposing the study
participants at unsafe levels. While data
use certifications (DUCs) or access appli-
cations (DAAs) generally specify that users
with data access should protect individual
confidentiality, not attempt to identify
individuals, and not sell or share con-
trolled-access data, they are less specific
about how data products (e.g., derived
SNP-specific statistics) can be appropriate-
ly shared or published. It is difficult to
ascertain whether the secondary posting
we found violated any data use agreements
or was in fact conducted without knowl-
edge of the data use agreements; however,
these examples illustrate that, even with
data access protections in place, there will
always be a potential risk of re-posting of
results by third parties. This suggests that
clearer guidance regarding appropriate
disclosure of derived data is needed in
DUCs and DAAs. Once results are posted
publicly, they cannot be deemed safe even
if posted results are eventually retracted,
since backups may have been created. In
our opinion, controlled access models have
decreased the overall risk for results misuse
across studies, but the examples of re-
posting uncovered illustrate that controlled
access is not fool-proof.
Given the small, but significant, number
of studies currently at risk for misuse, our
study provides evidence that the concerns
raised about GWAS results misuse are
indeed relevant to current reporting pro-
cedures for GWAS results. The increasing
use of massively parallel next generation
sequencing technology to conduct whole-
exome, whole-genome, and whole-tran-
scriptome sequencing studies for common
diseases in large populations will provide a
larger set of low frequency and private
genetic variants that may allow easier
identification of individual participants in
research studies [9]. Direct chromosomal
phasing of sequenced haplotypes could
also increase the potential for individual
identification. Deep sequencing promises
valuable new research results, but the
posting of aggregate sequencing-derived
results may create risks for misuse. Risks
for identification may increase with deep
sequencing of families with highly pene-
trant disease or in populations that are
discrete geographically or ethnically.
Thus, research regarding risks of identifia-
bility and guidelines for data sharing
should also be considered urgently for
the rapidly accumulating body of genome-
wide sequencing data in large populations.
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